Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men

@article{Feifel2008PharmacokineticsAT,
  title={Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men},
  author={Ulrich Feifel and Gudrun Ch. Wallenstein and Karl-Ludwig Rominger and Dirk Trommeshauser and Juliane Platz},
  journal={International Journal of Chronic Obstructive Pulmonary Disease},
  year={2008},
  volume={3},
  pages={397 - 404}
}
Data are presented from two randomized, double-blind, placebo-controlled studies in which the tolerability of tiotropium Respimat Soft MistTM Inhaler (SMI), a new-generation, propellant-free device for use in COPD, and the ocular safety oftiotropium were examined. In Study 1, 36 healthy males received tiotropium 8, 16, or 32 microg (n = 9/dose) or placebo (n = 3/dose level), administered once daily via Respimat SMI for 14 days. Safety and pharmacokinetics were evaluated. In Study 2, 48 healthy… CONTINUE READING
4 Citations
25 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Efficacy in COPD patients of tiotropium administered via the Respimat Soft Mist Inhaler (SMI) compared to HandiHaler (HH)

  • JA Van Noord, G Cornelissen, JL Aumann
  • Eur Respir J,
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…